gptkbp:instance_of
|
gptkb:depression
|
gptkbp:administered_by
|
oral tablet
|
gptkbp:approves
|
gptkb:1959
gptkb:FDA
|
gptkbp:available_on
|
generic drug
|
gptkbp:brand
|
Nardil
|
gptkbp:casnumber
|
51-71-8
|
gptkbp:chemical_formula
|
C12 H12 N2 O3
|
gptkbp:class
|
gptkb:depression
hydrazine derivative
|
gptkbp:clinical_trial
|
depression treatment
anxiety treatment
|
gptkbp:composed_by
|
reduction of phenylhydrazine
|
gptkbp:contraindication
|
gptkb:pheochromocytoma
liver disease
heart disease
history of stroke
|
gptkbp:developed_by
|
gptkb:Parke-Davis
|
gptkbp:discovery_year
|
1950s
|
gptkbp:dosage_form
|
15 to 90 mg per day
|
https://www.w3.org/2000/01/rdf-schema#label
|
Phenelzine
|
gptkbp:interacts_with
|
tyramine
opioids
stimulants
certain antidepressants
|
gptkbp:lifespan
|
11 to 16 hours
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
gptkbp:mechanism_of_action
|
inhibits monoamine oxidase
|
gptkbp:metabolism
|
liver
|
gptkbp:related_to
|
mental health treatment
MAO inhibitors
psychotropic drugs
antidepressant medications
neurotransmitter modulation
|
gptkbp:requires
|
prescription only
|
gptkbp:side_effect
|
dizziness
nausea
seizures
insomnia
dry mouth
weight gain
hypertensive crisis
sexual dysfunction
peripheral edema
serotonin syndrome
|
gptkbp:used_for
|
gptkb:depression
anxiety disorders
|
gptkbp:bfsParent
|
gptkb:Sunovion_Pharmaceuticals
gptkb:Monoamine_oxidase_inhibitors
|
gptkbp:bfsLayer
|
7
|